These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 7302567)
1. Cancer institute's drug program reproved. Sun M Science; 1981 Nov; 214(4523):887-9. PubMed ID: 7302567 [No Abstract] [Full Text] [Related]
2. An analysis of the relationship between human experimentation and drug discovery in the United States. DeFelice SL Drug Metab Rev; 1974; 3(1):167-84. PubMed ID: 4609707 [No Abstract] [Full Text] [Related]
3. The standard of disclosure in human subject experimentation. Morin K J Leg Med; 1998 Jun; 19(2):157-221. PubMed ID: 9658739 [No Abstract] [Full Text] [Related]
4. The case for patient access to experimental therapy. Delaney M J Infect Dis; 1989 Mar; 159(3):416-9. PubMed ID: 2915165 [No Abstract] [Full Text] [Related]
7. Recombinant DNA Advisory Committee: minutes of meeting, 14 Jan 1993. U.S. National Institutes of Health. Recombinant DNA Advisory Committee Hum Gene Ther; 1993 Aug; 4(4):529-44. PubMed ID: 11643161 [No Abstract] [Full Text] [Related]
8. Nondevelopmental research on human subjects: the impact of the recommendations of the National Commission. Levine RJ Fed Proc; 1977 Sep; 36(10):2359-64. PubMed ID: 892005 [No Abstract] [Full Text] [Related]
9. Waivers proposed for emergency studies. Wolfgang L Science; 1995 Oct; 270(5233):25-6. PubMed ID: 7569946 [No Abstract] [Full Text] [Related]
10. New rules for new drugs: the challenge of AIDS to the regulatory process. Edgar H; Rothman DJ Milbank Q; 1990; 68(Suppl. 1):111-42. PubMed ID: 11650413 [TBL] [Abstract][Full Text] [Related]
11. After deaths, F.D.A. is proposing stiffer rules on drug experiments. Hilts PJ N Y Times Web; 1993 Nov; ():A1, C6. PubMed ID: 11647958 [No Abstract] [Full Text] [Related]
13. The assault on David Baltimore. Kevles DJ New Yorker; 1996 May; 72(13):94-98, 100-104, 106-109. PubMed ID: 11654450 [No Abstract] [Full Text] [Related]
14. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures. Dunbar MM Food Drug Cosmet Law J; 1991 Sep; 46(5):673-706. PubMed ID: 11651380 [No Abstract] [Full Text] [Related]
15. Faith (healing), hope and charity at the FDA: the politics of AIDS drug trials. Annas GJ Villanova Law Rev; 1989 Sep; 34(5):771-97. PubMed ID: 11651162 [No Abstract] [Full Text] [Related]
16. Duke's hazards. Did medical experiments put patients needlessly at risk? Kaplan S; Brownlee S US News World Rep; 1999 May; 126(20):66-8, 70. PubMed ID: 10387890 [No Abstract] [Full Text] [Related]
17. Making clinical trials safer for human subjects. Baram M Am J Law Med; 2001; 27(2-3):253-82. PubMed ID: 11467112 [No Abstract] [Full Text] [Related]
18. The IRB's role in assessing the generalizability of non-NIH-funded clinical trials. Weijer C IRB; 1998; 20(2-3):1-5. PubMed ID: 11656912 [No Abstract] [Full Text] [Related]
20. For first time, gene therapy is tested on cancer patients. Angier N N Y Times Web; 1991 Jan; ():A1, A18. PubMed ID: 11646836 [No Abstract] [Full Text] [Related] [Next] [New Search]